Skip to content

S. 527 · 119th Congress (2025–2027)

Prescription Pricing for the People Act of 2025

Prescription Pricing for the People Act of 2025

This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.

The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.

The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.

Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.

Show official title

A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.

Reported

This bill’s path

This is S. 527’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Chuck Grassley (R-IA)
Cosponsors
13 cosponsors

10 original · 3 later

7 R · 6 D

  1. Sen. Richard Blumenthal (D-CT)· Original · Feb 11, 2025
  2. Sen. Maria Cantwell (D-WA)· Original · Feb 11, 2025
  3. Sen. Shelley Moore Capito (R-WV)· Original · Feb 11, 2025
  4. Sen. Christopher A. Coons (D-DE)· Original · Feb 11, 2025
  5. Sen. Mazie K. Hirono (D-HI)· Original · Feb 11, 2025
  6. Sen. James Lankford (R-OK)· Original · Feb 11, 2025
  7. Sen. Roger Marshall (R-KS)· Original · Feb 11, 2025
  8. Sen. Tommy Tuberville (R-AL)· Original · Feb 11, 2025
  9. Sen. Thom Tillis (R-NC)· Original · Feb 11, 2025
  10. Sen. Peter Welch (D-VT)· Original · Feb 11, 2025
  11. Sen. John Boozman (R-AR)· Later · Apr 2, 2025
  12. Sen. Marsha Blackburn (R-TN)· Later · Apr 7, 2025
  13. Sen. Raphael G. Warnock (D-GA)· Later · Jul 9, 2025
Policy area
Commerce
Subjects
  • Business ethics
  • Business records
  • Competition and antitrust
  • Congressional oversight
  • Consumer affairs
  • Health care costs and insurance
  • Health information and medical records
  • Inflation and prices
  • 3 more
    • Prescription drugs
    • Retail and wholesale trades
    • Supply chain

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Feb 11, 2025 – Apr 10, 2025
    1. Referred to committee

      Read twice and referred to the Committee on the Judiciary.

      Sources
    2. Ordered reported

      Committee on the Judiciary. Ordered to be reported without amendment favorably.

      Sources
    3. Reported by committee

      Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

      Sources

Committees

  1. SenateJudiciaryReferred Feb 11, 2025 · Markup Apr 3, 2025 · Reported Apr 10, 2025
    1. Apr 3, 2025 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (2)
  1. Prescription Pricing for the People Act of 2025

    Display title, Short title · Reported to Senate, Introduced in Senate

  2. A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.

    Official title · Introduced in Senate